Sentences with phrase «new immune therapies»

Another major focus of the Center is to generate new immune therapies for CANCER prevention or recurrence or for treatment.

In this webinar we will discuss the latest advances in mouse models for cancer research and how they are being applied to help us understand the pathways and mechanisms involved in new immune therapies.

Physician Peter Bach at Memorial Sloan Kettering Cancer Center is appalled at the sky - high price of cancer treatments in the United States, and he is watching new immune therapies drive them higher still.

Let's do this new immune therapy.

Not exact matches

Basically, CAR - T therapy involves taking a patient's own immune «killer» T - cells, inserting new genetic code into those cells which turn them into cancer - hunters that can home in on malignant B - cells (another kind of immune cell), and then pumping these specialized leukemia - busting cells back into the patient.

For example, we've seen new discoveries in health care recently, especially in immuno - oncology therapies, which help the immune systems of cancer patients recognize and destroy cancerous cells.

During the sessions, U.S. and Cuban scientists explored such topics as the molecular mechanisms cancer cells employ to evade the body's immune system, new tools to image and manipulate that system, and ways to rethink how such therapies can best be deployed to reach patients where they receive health services.

Revving up the immune system to combat a wide variety of tumor types may take cancer therapy in a new direction, says Khaled Barakat, a computational scientist at the University of Alberta in Canada, who was not involved in the study.

More precise application of immuno - therapies and the development of new approaches requires knowing the detailed immune landscape of individual patients and tumors.

Wrangle and Rubinstein's therapy is a combination of a checkpoint drug, nivolumab, with a new and powerful immune stimulation drug, ALT - 803.

«Steep funding cuts for the federal health agencies are counterproductive at a time when innovative research is moving us closer to identifying solutions for rare diseases, new prevention strategies to protect Americans from deadly and costly conditions, advances in gene therapy, new technologies for understanding the brain, and treatments that harness the ability of our immune system to fight cancer.»

«Our findings results suggest a new strategy for immune system - based therapies for cancer,» says the study's senior author, Harvey Cantor, MD, of Dana - Farber and Harvard.

With the potential to affect such a diverse array of neurological ailments, many of which have no known therapy, the hope is that an improved understanding of immune - CNS interactions will bring to light new paradigms for preventing and treating neurological disease.

«Our study reveals a new mechanism that could be harnessed for biological therapies for lupus and other autoimmune diseases, where the immune system mistakenly targets the body's own cells,» says senior study author Boris Reizis, PhD, professor of Pathology and Medicine at NYU Langone.

Oral immunotherapy for peanut allergy induces early, distinct changes in immune T - cell populations that potentially may help researchers determine which people will respond well to the therapy and which immune mechanisms are involved in the response, a new study suggests.

He hopes that further studies may identify novel approaches to immune - based cancer therapy or reveal new drug targets for inflammatory diseases.

Diabetes researchers are considering various replacements for insulin injections: Transplanting new pancreatic islet cells that make insulin, coaxing the patient's own islets to regenerate, or treating diabetics early in the disease with immune - suppressing therapies to prevent their body from destroying the rest of their pancreatic islets.

«It is expected that this study will lay the foundation for developing a new class of potent and effective cancer therapies and the development of reagents targeting epigenetic events in immune - mediated diseases as well as other epigenetically - influenced diseases,» said Alani, who also is chief of dermatology at Boston Medical Center.

A new wave of potential immune therapies aims to target the network of complex sugars that coat cancer cells, Esther Landhuis reported in «Cancer's sweet cloak» (SN: 4/1/17, p. 24).

«The control of immune cell entry into the joint represents a major point at which new therapies could be developed to reduce the symptoms of inflammatory arthritis,» says Luster, who is the Harrison Professor of Medicine at Harvard Medical School.

In June 2002, for example, a young girl treated with a new genetic therapy developed at the San Raffaele Hospital in Milan was cured of severe immune deficiency syndrome.

In a letter to the New England Journal of Medicine, a Massachusetts General Hospital (MGH) research team reports a remarkable treatment response in a patient participating in a clinical trial of a novel immune - system - based cancer therapy.

The ability of these children to maintain an intact immune system in the face of ongoing viral replication and in the absence of antiretroviral therapy can provide us with new insights into hitherto unknown defense mechanisms, which could eventually benefit other HIV patients,» says Professor Oliver T. Keppler, Chair of Virology at the Pettenkofer Institute, and former head of the German Reference Center for Retroviruses in Frankfurt am Main.

For patients, down the road Dr. Ohashi envisions a new era of combined therapies to simultaneously target and kill these suppressive cells while augmenting the immune response against cancer.

Kole Roybal is the 2018 grand prize winner of the inaugural Sartorius & Science Prize for Regenerative Medicine & Cell Therapy, for developing a new class of T cell immunotherapies that can be fine - tuned to better help the immune system recognize cancer and initiate precise therapeutic action against the disease.

This new understanding may help to increase the effectiveness of immune - based therapies against cancer.

Orchestrating a successful immune attack against tumors has proven difficult so far, but a new study from MIT suggests that such therapies could be improved by simultaneously activating both arms of the immune system.

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).

The new research indicates that, in addition to using powerful antibiotics to fight off infections in patients with sepsis, immunotherapy drugs that boost the immune system may be an effective therapy.

Dr. Martinez - Agosto noted, «Looking at the functionality of these genes and their effect on the immune response has great potential for accelerating the development of new targeted therapies.»

A new technique inspired by the immune systems of microorganisms could be a boon for gene therapy.

Two teams of scientists suggest that activating immune cells in fat can convert the tissue from a type of fat that stores energy to one that burns it, opening up potential new therapies for obesity and diabetes.

The unit is currently working on bringing to market a new gene therapy for the immune disease ADA - SCID, which is thought to affect only 350 children worldwide.

New research out of the University of Michigan supports combining two approaches to fight back against gliomas: attacking the tumor with gene therapy while enhancing the immune system's ability to fight it, too.

«New way to unmask melanoma cells to the immune system: Lab studies show promise for a clinical trial aimed at improving current immune therapies.»

«While there is understandable excitement around new therapies that enlist the immune system to fight cancer, we are still in a situation where greater than half of patients don't respond in melanoma and the response rate is even worse in other cancer types,» Hanks said.

A new study, presented today at The International Liver Congress ™ 2016 in Barcelona Spain, demonstrates that the use of antiviral therapy for patients in the immune tolerant phase of Hepatitis B (HBV) prolongs overall survival and reduces the risk of the most common form of liver cancer (Hepatocellular Carcinoma, HCC) and scarring of the liver (cirrhosis).

And while new therapies have been effective in releasing the immune system's restraints to unleash the body's own cancer - fighting powers, they only work in about half of melanoma patients and often lose their potency as the cancer develops resistance.

The results, published today in Nature Immunology, suggest a common biochemical thread to multiple diseases and point the way to a new class of therapies that could treat chronic inflammation in these non-infectious diseases without crippling the immune system.

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

In the new study, the researchers used a combination of four different therapies to activate both of the immune system's two branches, producing a coordinated attack that led to the complete disappearance of large, aggressive tumors in mice.

But if the immune system is involved in the new - found problems, it provides additional impetus to develop «personalised» therapies, in which neurons are grown from a patient's own cells, and so should be less likely to provoke an immune reaction.

«We reported last year that this treatment can greatly reduce the amount of virus that's present in someone's blood,» Dr. Schoofs adds, «but we wanted to follow the patients for a longer period of time to study how their immune systems were adapting to the new therapy.»

The new findings, published online in the journal Molecular Cancer Therapeutics, show that combining rapamycin with a gene therapy approach enhanced the animals» ability to summon immune cells called CD8 + T cells to kill tumor cells directly.

New research into Amyotrophic Lateral Sclerosis (ALS)-- also known as motor neuron disease — shows that specific immune cells may help slow progression of the disease, an important step towards developing new therapies to treat patienNew research into Amyotrophic Lateral Sclerosis (ALS)-- also known as motor neuron disease — shows that specific immune cells may help slow progression of the disease, an important step towards developing new therapies to treat patiennew therapies to treat patients.

Chi said the new understanding of autophagy's role in regulatory T cells could enable a two-fold approach to immune therapy for cancers.

Her work - published in December 2007 - revealed genes involved in drug resistance and in evading the immune system, giving researchers potential targets for new therapies and vaccines.

Geneva, Switzerland, 26 March 2014 — A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

«Brain immune system is key to recovery from motor neuron degeneration: Results in study point to new approaches for ALS therapy.»

«It combines these with a new and exciting therapy called immunotherapy — a treatment which harnesses the body's immune system to help with fighting cancer.»